Patents Assigned to Serodus AS
  • Dual TNFR1 antagonists and TNER2 agonists for use in renal diseases
    Patent number: 12083097
    Abstract: The present invention relates to certain 2,4-diphenyl-1,3-dioxanes that are capable of reducing Tumor necrosis factor receptor 1 (sTNFR1) and capable of increasing Tumor necrosis factor receptor 2 (sTNFR2) and their use in the treatment of specific subpopulations with a renal disease such as diabetic nephropathy.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: September 10, 2024
    Assignee: SERODUS AS
    Inventors: Eva Steiness, Torben Frank Skarsfeldt
  • 5-HT4 receptor antagonists for the treatment of heart failure
    Patent number: 8829028
    Abstract: This invention provides the use of a 5-HT4 receptor antagonist in the manufacture of a medicament for treating or preventing heart failure. Particular heart disorders to be treated are selected from the group comprising chronic heart failure, congestive heart failure, chronic congestive heart failure and heart failure resulting from ischaemic heart disease. Methods of treating heart failure using 5-HT4 receptor antagonists and pharmaceutical compositions containing 5-HT4 receptor antagonists are also provided.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: September 9, 2014
    Assignee: Serodus AS
    Inventor: Finn Olav Levy
  • 5-HT RECEPTOR MODULATING COMPOUNDS
    Publication number: 20120094989
    Abstract: The present invention relates to compounds having 5-hydroxytryptamine receptor modulating activity, in particular compounds having an acidic moiety held distant from the 5-HT pharmacophore by a rigid linker group, to compositions containing such compounds and methods of treatment using them. Such compounds have an increased affinity for the 5-HT receptor and a reduced hERG effect. Certain compounds of the invention further exhibit an angiotensin II receptor modulating activity. Claimed are compounds of formula (I): HT-L-A. HT is a 5-HT receptor modulating moiety containing a basic nitrogen atom; A is an acid moiety; L is a linker moiety.
    Type: Application
    Filed: April 1, 2010
    Publication date: April 19, 2012
    Applicant: SERODUS AS
    Inventors: Jo Klaveness, Bjame Brudeli, Finn Olav Levy, Lise Roman Moltzau, Trygve Gulbrandsen
  • Modulators of peripheral 5-HT receptors
    Patent number: 7834010
    Abstract: The invention relates to modulators of peripheral 5-HT receptors, particularly 5-HT4 receptors, said modulators essentially selective for peripheral 5-HT receptors over receptors of the central nervous system. The invention allows for the treatment, amongst others, of gastrointestinal disorders, lower urinary tract disorders, and cardiovascular disorders without side effects related to CNS activity.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: November 16, 2010
    Assignee: Serodus AS
    Inventors: Jo Klaveness, Finn Olav Levy, Bjarne Brudeli
  • 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE
    Publication number: 20090169545
    Abstract: This invention provides the use of a 5-HT4 receptor antagonist in the manufacture of a medicament for treating or preventing heart failure. Particular heart disorders to be treated are selected from the group comprising chronic heart failure, congestive heart failure, chronic congestive heart failure and heart failure resulting from ischaemic heart disease. Methods of treating heart failure using 5-HT4 receptor antagonists and pharmaceutical compositions containing 5-HT4 receptor antagonists are also provided.
    Type: Application
    Filed: February 17, 2009
    Publication date: July 2, 2009
    Applicant: SERODUS AS
    Inventor: FINN OLAV LEVY